Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr

Autor: Félicien Le Louedec, Florent Puisset, Fabienne Thomas, Étienne Chatelut, Mélanie White‐Koning

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1208-1220 (2021)

Abstract Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model‐informed precision dosing (MIPD) approach. The mapbayr package was developed to perform maximum a posteriori Bayesian estimation (MAP‐BE) in R from any

Externí odkaz: https://doaj.org/article/c86571642f3042ac94a9ffd97f1904dc

Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study

Autor: Florent Puisset, Félicien Le Louedec, Florence Dalenc, Lorène Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, Mony Ung, Camille Vinson, Sophie Perriat, Sandrine Pacher, Etienne Chatelut, Mélanie White Koning

Publikováno v: British Journal of Clinical Pharmacology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36bb36b307ab21503bf242bf308eba95
https://doi.org/10.1111/bcp.15702

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease

Autor: Florent, Puisset, Mélanie, White-Koning, Nassim, Kamar, Antoine, Huart, Frédérique, Haberer, Hélène, Blasco, Chantal, Le Guellec, Thierry, Lafont, Anaïs, Grand, Lionel, Rostaing, Etienne, Chatelut, Jacques, Pourrat

Publikováno v: British journal of clinical pharmacology. 76(5)

Both rituximab and plasmapheresis can be associated in the treatment of immune-mediated kidney diseases. The real impact of plasmapheresis on rituximab pharmacokinetics is unknown. The aim of this study was to compare rituximab pharmacokinetics betwe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8a7131478f9e4956ee3bd7ce9de6018f
https://pubmed.ncbi.nlm.nih.gov/23432476

Cancer adolescent pathway in France between 1988 and 1997

Autor: Mélanie White-Koning, Nabil Maarouf, Laurence Brugières, Patricia Delafosse, Brigitte Trétarre, Danièle Sommelet, Anne-Valérie Guizard, Emmanuel Desandes, Angelina Marr, Brigitte Lacour, Christine Cotte, Michel Velten, Arlette Danzon

Publikováno v: European Journal of Oncology Nursing
European Journal of Oncology Nursing, Elsevier, 2007, 11 (1), pp.74-81. ⟨10.1016/j.ejon.2006.04.036⟩
European Journal of Oncology Nursing, Elsevier, 2007, 11 (1), pp.74-81. 〈10.1016/j.ejon.2006.04.036〉

International audience; We report an adolescent cancer pathway from referral, through diagnosis and treatment, to follow-up in France. All cases of cancer among 15-19 years, diagnosed from 1988 to 1997, recorded by nine French population-based cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3be7df0a34317b043a2c7b69c081ac
https://hal.archives-ouvertes.fr/hal-00492897

Analyse pharmacocinétique-pharmacodynamique de l'ibrutinib dans le contexte d'une étude multidisciplinaire pour le traitement de la leucémie lymphoïde chronique

Autor: Gallais, Fanny

Publikováno v: Cancer. Université Paul Sabatier-Toulouse III, 2020. Français. ⟨NNT : 2020TOU30076⟩

Ibrutinib, the first-in-class Bruton Tyrosine Kinase inhibitor, is indicated for the treatment of chronic lymphocytic leukemia (CLL). CLL is characterized by the accumulation of abnormal B cells in the bone marrow, lymphoid organs and blood. Ibrutini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::53963f93843ad54b549c67f1f53cd1d8
https://tel.archives-ouvertes.fr/tel-03098547/document